Sep 07, 2022 / 07:00AM GMT
Matthew Carlisle Sykes - Goldman Sachs Group, Inc., Research Division - Research Analyst
Great. Well, thank you, everybody, for joining us today. My name is Matt Sykes. I'm the senior life sciences tools and diagnostics analyst out of the U.S. I have the pleasure of welcoming QIAGEN to our conference this morning. We have Roland Sackers, the Chief Financial Officer; and John Gilardi, the VP of Communications and IR. Roland, John, thanks for joining us today.
Roland Sackers - Qiagen N.V. - CFO, MD & Member of Management Board
Thanks for having us.
Matthew Carlisle Sykes - Goldman Sachs Group, Inc., Research Division - Research Analyst
So maybe if we just let you kind of set the stage a little bit, talk about the most recent quarter and your expectations for the rest of the year.
Roland Sackers - Qiagen N.V. - CFO, MD & Member of Management Board
Yes. Happy to do so. And yes, most of you are familiar faces. So I'm going to keep it brief and looking on the number of
Qiagen NV at Goldman Sachs European Medtech and Healthcare Services Conference Transcript
Feb 11, 2024
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers